Literature DB >> 11360217

Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies.

I Sereti1, H C Lane.   

Abstract

Human immunodeficiency virus (HIV) infection leads to a state of CD4 lymphopenia and generalized immune activation with subsequent development of opportunistic infections and neoplasms. The use of highly active antiretroviral treatment has dramatically improved the clinical outcome for HIV-infected patients, but the associated cost and toxicity and the eventual development of drug resistance have underscored the need for additional therapeutic strategies. Immune-based therapies, such as treatment with cytokines or immunosuppressants, adoptive immunotherapy, and therapeutic immunizations, are being intensely investigated as potential supplements to antiretroviral therapy. Although much data have been generated as a result of these efforts, to date there has been little evidence of the clinical efficacy of these strategies. Randomized clinical studies remain critical in evaluating the clinical significance and the role of immune-based therapies in the therapeutic armamentarium against HIV.

Entities:  

Mesh:

Year:  2001        PMID: 11360217     DOI: 10.1086/320758

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

Review 1.  The immunocompromised host: HIV infection.

Authors:  James M Beck
Journal:  Proc Am Thorac Soc       Date:  2005

2.  CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo.

Authors:  Erika Schlaepfer; Annette Audigé; Barbara von Beust; Vania Manolova; Markus Weber; Helene Joller; Martin F Bachmann; Thomas M Kundig; Roberto F Speck
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

3.  Identification and cloning of a cryptococcal deacetylase that produces protective immune responses.

Authors:  Carmelo Biondo; Concetta Beninati; Demetrio Delfino; Marco Oggioni; Giuseppe Mancuso; Angelina Midiri; Mauro Bombaci; Giuseppe Tomaselli; Giuseppe Teti
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

4.  Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection.

Authors:  Ven Natarajan; Richard A Lempicki; Irini Sereti; Yunden Badralmaa; Joseph W Adelsberger; Julia A Metcalf; Darue A Prieto; Randy Stevens; Michael W Baseler; Joseph A Kovacs; H Clifford Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

5.  Interleukin-10-secreting T cells define a suppressive subset within the HIV-1-specific T-cell population.

Authors:  Eirik A Torheim; Lishomwa C Ndhlovu; Frank O Pettersen; Trine-Lise Larsen; Aashish R Jha; Knut M Torgersen; Dag Kvale; Douglas F Nixon; Kjetil Taskén; Einar M Aandahl
Journal:  Eur J Immunol       Date:  2009-05       Impact factor: 5.532

6.  IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.

Authors:  Irini Sereti; Richard M Dunham; John Spritzler; Evgenia Aga; Michael A Proschan; Kathy Medvik; Catherine A Battaglia; Alan L Landay; Savita Pahwa; Margaret A Fischl; David M Asmuth; Allan R Tenorio; John D Altman; Lawrence Fox; Susan Moir; Angela Malaspina; Michel Morre; Renaud Buffet; Guido Silvestri; Michael M Lederman
Journal:  Blood       Date:  2009-04-20       Impact factor: 22.113

Review 7.  Abnormalities in host defense associated with HIV infection.

Authors:  James M Beck
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

8.  Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.

Authors:  Brian O Porter; Kara B Anthony; Jean Shen; Barbara Hahn; Chris E Keh; Frank Maldarelli; William C Blackwelder; Henry Clifford Lane; Joseph A Kovacs; Richard T Davey; Irini Sereti
Journal:  AIDS       Date:  2009-01-14       Impact factor: 4.177

9.  CD127 and CD25 expression defines CD4+ T cell subsets that are differentially depleted during HIV infection.

Authors:  Richard M Dunham; Barbara Cervasi; Jason M Brenchley; Helmut Albrecht; Amy Weintrob; Beth Sumpter; Jessica Engram; Shari Gordon; Nichole R Klatt; Ian Frank; Donald L Sodora; Daniel C Douek; Mirko Paiardini; Guido Silvestri
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.